Two-field Versus Three-field Lymphadenectomy in Thoracic Esophageal Carcinoma Without Cervical Lymph Node Involvement
- Conditions
- Esophageal Cancer
- Interventions
- Procedure: Two-field lymphadenectomyProcedure: Three-field lymphadenectomy
- Registration Number
- NCT02448953
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Brief Summary
The purpose of this study is to compare the lymph node dissection results and prognosis in thoracic esophageal carcinoma patients without cervical lymph node involvement by preoperative CT and/or ultrasound treated by two-field lymphadenectomy or three-field lymphadenectomy.Another purpose of this study is to clarify whether the lymph node along the right recurrent laryngeal nerve can be taken as the sentinel lymph node which is able to indicate neck lymph node metastasis and necessity for three-field lymphadenectomy.
- Detailed Description
Esophageal carcinoma is a prevalent and aggressive malignant disease with poor prognosis in China. Complete surgical resection with systemic lymph node dissection remains the most effective treatment method for this malignancy. Although tree-field lymph node dissection was reported to be effective in improving long-term survival in Japan,there is no enough evidences yet to demonstrate that three field lymph node dissection is superior to two field lymph node dissection in reducing postoperative recurrence and improving long-term survival. In this study, the dissection of lymph node adjacent to the right recurrent laryngeal nerve would be performed and examined routinely by intraoperative frozen-section. If the lymph node is positive, three field lymph node dissection(Cervical-thoracic-upper abdominal lymphadenectomy) will be performed, if negative, the patients will be randomly assigned either to three-field lymphadenectomy group or two-field lymphadenectomy group. The purpose of this large scale multi-center trial is to compare the lymph node dissection results and prognosis in thoracic esophageal carcinoma without cervical lymph node involvement treated by three-field lymphadenectomy or two-field lymphadenectomy and clarify whether the lymph node along the right recurrent laryngeal nerve could be taken as sentinel lymph node indicating neck lymph node metastasis and necessity of three-field lymphadenectomy.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 786
- Patients with histologically confirmed squamous cell esophageal cancer, without any previous anti-tumor therapy;
- Preoperative clinical TNM stage:cT1b-3N0-1M0;
- Adequate cardiopulmonary, liver, brain and kidney functions for esophagectomy either via right thoracotomy or VATS;
- No evidence of suspicious neck lymph node metastasis (LN short diameter < 0.8cm or LN short/long diameter <0.65 by cervical CT and/or ultrasound);
- Willing to participate the clinical trial and sign the informed consent before being enrolled into clinical trail
- Previous use of anti-cancer therapy;
- Preoperative clinical TNM stage: N2-3 or M1;
- Inadequate cardiopulmonary,liver, brain and kidney function for surgery;
- Previous malignancy history.
- Suspicious neck lymph node metastasis (LN short diameter ≧0.8cm or LN short/long diameter ≧0.65 by cervical CT and/or ultrasound);
- Unwilling to participate the clinical trial and refuse to sign informed consent.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description negative lymph node Three-field lymphadenectomy lymph node along the right recurrent laryngeal nerve should be confirmed negative by intraoperative frozen pathology examination positive lymph node Three-field lymphadenectomy lymph node along the right recurrent laryngeal nerve should be confirmed negative by intraoperative frozen pathology examination negative lymph node Two-field lymphadenectomy lymph node along the right recurrent laryngeal nerve should be confirmed negative by intraoperative frozen pathology examination
- Primary Outcome Measures
Name Time Method Long term survival 5 years
- Secondary Outcome Measures
Name Time Method Disease free survival 5 years Locoregional recurrence 5 years Postoperative complications 3 years
Trial Locations
- Locations (1)
Cancer hospital, Chinese Academy of Medical Sciences
🇨🇳Beijing, Beijing, China